Van De Sijpe, Greet http://orcid.org/0000-0003-1475-6178
Beuselinck, Benoit http://orcid.org/0000-0001-7427-9102
Van Nieuwenhuyse, Tine http://orcid.org/0000-0002-0898-904X
Poncelet, Roxanne http://orcid.org/0000-0002-2093-958X
Bechter, Oliver http://orcid.org/0000-0003-0667-3284
Albersen, Maarten http://orcid.org/0000-0002-6763-6586
Roussel, Eduard http://orcid.org/0000-0002-7835-5536
Baldewijns, Marcella http://orcid.org/0000-0002-0882-2944
Tack, Jan http://orcid.org/0000-0002-3206-6704
Spriet, Isabel http://orcid.org/0000-0001-6342-0676
Article History
Received: 6 February 2020
Accepted: 14 May 2020
First Online: 30 May 2020
Compliance with ethical standards
:
: Beuselinck Benoit received an unrestricted research grant from Bristol-Myers-Squibb for other research projects and honorarium from Merck, Pfizer, Bristol-Myers-Squibb, Ipsen, and Astra Zeneca. Tack Jan has given scientific advice to Sofar, Takeda, and Truvion, has received research support from Sofar, and has served on the Speaker bureau for Takeda and Truvion. The other authors report no conflict of interest.
: The hospital ethics committee approved this retrospective study.
: Not applicable